B1MR34 Stock Overview
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
BioMarin Pharmaceutical Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$213.90 |
| 52 Week High | US$245.14 |
| 52 Week Low | US$195.19 |
| Beta | 0.32 |
| 1 Month Change | -2.77% |
| 3 Month Change | -7.09% |
| 1 Year Change | -10.10% |
| 3 Year Change | 0.64% |
| 5 Year Change | n/a |
| Change since IPO | 19.63% |
Recent News & Updates
Recent updates
Shareholder Returns
| B1MR34 | BR Biotechs | BR Market | |
|---|---|---|---|
| 7D | -9.2% | 1.0% | 0.5% |
| 1Y | -10.1% | -4.0% | 16.7% |
Return vs Industry: B1MR34 underperformed the BR Biotechs industry which returned -4.8% over the past year.
Return vs Market: B1MR34 underperformed the BR Market which returned 16.7% over the past year.
Price Volatility
| B1MR34 volatility | |
|---|---|
| B1MR34 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in BR Market | 8.6% |
| 10% least volatile stocks in BR Market | 2.3% |
Stable Share Price: B1MR34 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine B1MR34's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 3,401 | Alexander Hardy | www.biomarin.com |
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company’s commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase.
BioMarin Pharmaceutical Inc. Fundamentals Summary
| B1MR34 fundamental statistics | |
|---|---|
| Market cap | R$79.59b |
| Earnings (TTM) | R$1.07b |
| Revenue (TTM) | R$12.83b |
77.0x
P/E Ratio6.4x
P/S RatioIs B1MR34 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| B1MR34 income statement (TTM) | |
|---|---|
| Revenue | US$2.47b |
| Cost of Revenue | US$1.25b |
| Gross Profit | US$1.22b |
| Other Expenses | US$1.01b |
| Earnings | US$205.46m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.08 |
| Gross Margin | 49.34% |
| Net Profit Margin | 8.31% |
| Debt/Equity Ratio | 21.4% |
How did B1MR34 perform over the long term?
See historical performance and comparison